scholarly journals European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery

2021 ◽  
pp. ijgc-2021-002951 ◽  
Author(s):  
Christina Fotopoulou ◽  
François Planchamp ◽  
Tugce Aytulu ◽  
Luis Chiva ◽  
Alessandro Cina ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
European Society ◽  
Care Delivery ◽  
Advanced Ovarian Cancer ◽  
Operative Management ◽  
Evidence Based ◽  
Gynaecological Oncology ◽  
Operative Care ◽  
Management Of Complications ◽  
Development Group

The European Society of Gynaecological Oncology (ESGO) developed and established for the first time in 2016, and updated in 2020, quality indicators for advanced ovarian cancer surgery to audit and improve clinical practice in Europe and beyond. As a sequela of the continuous effort to improve oncologic care in patients with ovarian cancer, ESGO issued in 2018 a consensus guidance jointly with the European Society of Medical Oncology addressing in a multidisciplinary fashion 20 selected key questions in the management of ovarian cancer, ranging from molecular pathology to palliation in primary and relapse disease. In order to complement the above achievements and consolidate the promoted systemic advances and surgical expertise with adequate peri-operative management, ESGO developed, as the next step, clinically relevant and evidence-based guidelines focusing on key aspects of peri-operative care and management of complications as part of its mission to improve the quality of care for women with advanced ovarian cancer and reduce iatrogenic morbidity. To do so, ESGO nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of ovarian cancer (18 experts across Europe). To ensure that the guidelines are evidence based, the literature published since 2015, identified from a systematic search, was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 117 independent international practitioners in cancer care delivery and patient representatives.

European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery

2017 ◽  
Vol 27 (7) ◽  
pp. 1534-1542 ◽  
Author(s):  
Denis Querleu ◽  
François Planchamp ◽  
Luis Chiva ◽  
Christina Fotopoulou ◽  
Desmond Barton ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Decision Making ◽  
Surgical Management ◽  
Fallopian Tube ◽  
European Society ◽  
Scientific Evidence ◽  
Professional Experience ◽  
Evidence Based ◽  
Gynaecological Oncology ◽  
Development Group

MethodsThe European Society of Gynaecological Oncology council nominated an international multidisciplinary development group made of practicing clinicians who have demonstrated leadership and interest in the care of ovarian cancer (20 experts across Europe). To ensure that the statements are evidence based, the current literature identified from a systematic search has been reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group (expert agreement). The guidelines are thus based on the best available evidence and expert agreement. Before publication, the guidelines were reviewed by 66 international reviewers independent from the development group including patients representatives.ResultsThe guidelines cover preoperative workup, specialized multidisciplinary decision making, and surgical management of diagnosed epithelial ovarian, fallopian tube, and peritoneal cancers. The guidelines are also illustrated by algorithms.

European Society of Gynaecological Oncology Guidelines for the Management of Patients With Vulvar Cancer

2017 ◽  
Vol 27 (4) ◽  
pp. 832-837 ◽  
Author(s):  
Maaike H.M. Oonk ◽  
François Planchamp ◽  
Peter Baldwin ◽  
Mariusz Bidzinski ◽  
Mats Brännström ◽  
...  
Keyword(s):  
International Development ◽  
European Society ◽  
Vulvar Cancer ◽  
Scientific Evidence ◽  
Local Treatment ◽  
Distant Metastases ◽  
Evidence Based ◽  
Gynaecological Oncology ◽  
Patient Representatives ◽  
Development Group

ObjectiveThe aim of this study was to develop clinically relevant and evidence-based guidelines as part of European Society of Gynaecological Oncology’s mission to improve the quality of care for women with gynecologic cancers across Europe.MethodsThe European Society of Gynaecological Oncology Council nominated an international development group made of practicing clinicians who provide care to patients with vulvar cancer and have demonstrated leadership and interest in the management of patients with vulvar cancer (18 experts across Europe). To ensure that the statements are evidence based, the current literature identified from a systematic search has been reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group (expert agreement). The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 181 international reviewers including patient representatives independent from the development group.ResultsThe guidelines cover diagnosis and referral, preoperative investigations, surgical management (local treatment, groin treatment including sentinel lymph node procedure, reconstructive surgery), radiation therapy, chemoradiation, systemic treatment, treatment of recurrent disease (vulvar recurrence, groin recurrence, distant metastases), and follow-up.

scholarly journals The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer

2018 ◽  
Vol 28 (4) ◽  
pp. 641-655 ◽  
Author(s):  
David Cibula ◽  
Richard Pötter ◽  
François Planchamp ◽  
Elisabeth Avall-Lundqvist ◽  
Daniela Fischerova ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
European Society ◽  
Invasive Cervical Cancer ◽  
Locally Advanced ◽  
Evidence Based ◽  
Cervical Lesions ◽  
Gynaecological Oncology ◽  
Cancer Management ◽  
Fertility Sparing ◽  
Development Group

BackgroundDespite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer.ObjectiveThe European Society of Gynaecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide.MethodsThe ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives.ResultsThe guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.

Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update

2020 ◽  
Vol 30 (4) ◽  
pp. 436-440 ◽  
Author(s):  
Christina Fotopoulou ◽  
Nicole Concin ◽  
François Planchamp ◽  
Philippe Morice ◽  
Ignace Vergote ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Quality Indicators ◽  
European Society ◽  
Advanced Ovarian Cancer ◽  
Cancer Surgery ◽  
Gynaecological Oncology

Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery

2015 ◽  
Vol 137 (3) ◽  
pp. 406-411 ◽  
Author(s):  
Pierluigi Benedetti Panici ◽  
Violante Di Donato ◽  
Margherita Fischetti ◽  
Assunta Casorelli ◽  
Giorgia Perniola ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Abdominal Surgery ◽  
Postoperative Morbidity ◽  
Advanced Ovarian Cancer ◽  
Upper Abdominal Surgery ◽  
Management Of Complications ◽  
Upper Abdominal

scholarly journals Genomic-Based Therapy of Gynecologic Malignancies

2019 ◽  
Vol 48 (1) ◽  
pp. 84
Author(s):  
Maurie Markman
Keyword(s):  
Ovarian Cancer ◽  
Care Delivery ◽  
Advanced Ovarian Cancer ◽  
Standard Of Care ◽  
Parp Inhibitors ◽  
Current Status ◽  
Gynecologic Malignancies ◽  
Substantial Progress ◽  
Recurrent Endometrial Cancer ◽  
Tumor Types

<p>This paper will review the current status of genomic-based therapy of gynecologic malignancies. The routine “standard-of-care” delivery of targeted therapeutics based on the presence of specific molecular biomarkers in the management of the gynecologic malignancies has been delayed compared to the substantial progress made in several other tumor types.  However, relatively recently reported and rather robust phase 3 trial data have confirmed a potentially major role for PARP inhibitors as both active treatment and maintenance therapy of advanced ovarian cancer.  Further, data demonstrating the presence of a specific molecular phenotype (micro-satellite instability high – MSI-H) is a valid biomarker for the potential clinical utility of checkpoint inhibitor immunotherapy has relevance for all gynecologic malignancies, and particularly in the setting of metastatic or recurrent endometrial cancer.</p><p><strong>Conclusions. </strong>The introduction of PARP inhibitors into the oncology armamentarium has substantially impacted standard-of-care strategies in the management of ovarian cancer. It is anticipated that the results of ongoing and future trials will further define the role of genomic-based therapy in ovarian cancer and other gynecologic malignancies.</p>

Sign in / Sign up

Export Citation Format

Share Document